Skip to content

Effect of low- dose Erythromycin on the treatment of COPD

Effect of low- dose Erythromycin on the treatment of COPD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008820
Enrollment
Unknown
Registered
2016-07-11
Start date
2016-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients meeting the GOLD2015 diagnostic criteria for COPD.(a ratio of postbronchodilator forced expiratory volume in1 second [FEV1] to forced vital capacity of <70%,and a postbronchodilator FEV1 of <80% of the predicted value) 2. Patients aged 40 years and more; 3. Patients were past or present cigarette smokers with at least a 10 pack-year smoking history; 4. Patients were studied when clinically stable for at least 4 weeks following an exacerbation; no change in any therapy; no received systemic glucocorticoids.

Exclusion criteria

Exclusion criteria: 1. Combined with asthma, tuberculosis, lung cancer, Bronchiectasis and other severe respiratory diseases; 2. Combined with heart failure, long QT syndrome and arrhythmia; 3. Combined with severe digestive system diseases such as ulcer, hepatitis; 4. Combined with other serious diseases such as: nerve, endocrine, blood system diseases and kidney disease, rheumatism and malignant tumor; 5. Allergy to erythromycin or other severe adverse reactions, and patients can not cooperate with the researchers.

Design outcomes

Primary

MeasureTime frame
Exacerbations of COPD;

Secondary

MeasureTime frame
ling function;

Countries

China

Contacts

Public ContactZhong Xiaoning
xiaoningzhong@sina.com+86 13607881203

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026